News

Surgery adds little after successful chemo in metastatic breast cancer


 

SAN ANTONIO – In patients with metastatic breast cancer who responded favorably to initial chemotherapy, radiotherapy and surgical removal of primary tumors failed to enhance overall survival, a new study has shown.

In an interview at the San Antonio Breast Cancer Symposium, study investigator Dr. Rajendra Badwe offers his perspectives on loco-regional treatment vs. chemotherapy alone, and he discusses why surgical removal of primary tumors might be linked to later spread of metastatic disease.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

VIDEO: Idelalisib shows promise in refractory non-Hodgkin lymphoma
MDedge Hematology and Oncology
Sickle cell crises curtailed with experimental cellular adhesion inhibitor
MDedge Hematology and Oncology
VIDEO: What's ahead for chronic myelogenous leukemia?
MDedge Hematology and Oncology
ASCO slams federal cuts in its annual report
MDedge Hematology and Oncology
Pathologic complete response to HER2 therapy portends better outcomes
MDedge Hematology and Oncology
Radiotherapy can be omitted for many older breast cancer patients
MDedge Hematology and Oncology
VIDEO: Tumor-infiltrating lymphocytes may predict trastuzumab success
MDedge Hematology and Oncology
Dasatinib gives letrozole a boost in HR-positive advanced breast cancer
MDedge Hematology and Oncology
IBIS-II: Anastrozole highly effective in preventing breast cancer
MDedge Hematology and Oncology
No gain seen from adjuvant bevacizumab in HER2-positive disease
MDedge Hematology and Oncology